Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:conditionStudied |
B-cell acute lymphoblastic leukemia
|
| gptkbp:endPoint |
overall remission rate
|
| gptkbp:enrollment |
75 patients
|
| gptkbp:fullName |
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia (ALL)
|
| https://www.w3.org/2000/01/rdf-schema#label |
ELIANA trial
|
| gptkbp:location |
international
multicenter |
| gptkbp:number |
NCT02435849
|
| gptkbp:period |
Phase II
|
| gptkbp:population |
pediatric patients
young adult patients |
| gptkbp:principalInvestigator |
Stephan Grupp
|
| gptkbp:publicationYear |
2018
|
| gptkbp:publishedIn |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:result |
high remission rates
manageable safety profile |
| gptkbp:sponsor |
gptkb:Novartis
|
| gptkbp:startDate |
2015
|
| gptkbp:studiedDrug |
gptkb:tisagenlecleucel
|
| gptkbp:treatment |
gene therapy
|
| gptkbp:bfsParent |
gptkb:Chimeric_Antigen_Receptor_T-cell_therapy
|
| gptkbp:bfsLayer |
8
|